PDS Planning Inc Purchases 507 Shares of Thermo Fisher Scientific Inc. (NYSE:TMO)

PDS Planning Inc lifted its position in shares of Thermo Fisher Scientific Inc. (NYSE:TMO) by 22.1% during the fourth quarter, HoldingsChannel reports. The firm owned 2,798 shares of the medical research company’s stock after buying an additional 507 shares during the quarter. PDS Planning Inc’s holdings in Thermo Fisher Scientific were worth $1,456,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors also recently made changes to their positions in the company. Leelyn Smith LLC boosted its position in shares of Thermo Fisher Scientific by 3.3% during the fourth quarter. Leelyn Smith LLC now owns 7,208 shares of the medical research company’s stock worth $3,750,000 after purchasing an additional 228 shares in the last quarter. BlackDiamond Wealth Management LLC boosted its position in shares of Thermo Fisher Scientific by 6.4% during the fourth quarter. BlackDiamond Wealth Management LLC now owns 449 shares of the medical research company’s stock worth $234,000 after purchasing an additional 27 shares in the last quarter. Tocqueville Asset Management L.P. lifted its position in Thermo Fisher Scientific by 4.9% in the 4th quarter. Tocqueville Asset Management L.P. now owns 75,683 shares of the medical research company’s stock valued at $39,373,000 after acquiring an additional 3,553 shares in the last quarter. Flagship Wealth Advisors LLC bought a new stake in Thermo Fisher Scientific in the 4th quarter valued at $341,000. Finally, Cassady Schiller Wealth Management LLC lifted its position in Thermo Fisher Scientific by 89.2% in the 4th quarter. Cassady Schiller Wealth Management LLC now owns 70 shares of the medical research company’s stock valued at $36,000 after acquiring an additional 33 shares in the last quarter. 89.23% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

Several equities research analysts recently commented on TMO shares. Bank of America cut their price objective on shares of Thermo Fisher Scientific from $675.00 to $660.00 and set a “buy” rating on the stock in a research report on Friday, December 13th. Morgan Stanley boosted their price objective on shares of Thermo Fisher Scientific from $647.00 to $678.00 and gave the company an “overweight” rating in a research report on Friday, January 31st. UBS Group boosted their price objective on shares of Thermo Fisher Scientific from $700.00 to $715.00 and gave the company a “buy” rating in a research report on Friday, January 31st. Scotiabank lifted their price target on shares of Thermo Fisher Scientific from $605.00 to $650.00 and gave the company a “sector perform” rating in a research note on Monday, February 3rd. Finally, Sanford C. Bernstein upgraded shares of Thermo Fisher Scientific from a “market perform” rating to an “outperform” rating and set a $630.00 price target on the stock in a research note on Friday, January 10th. Four analysts have rated the stock with a hold rating and nineteen have given a buy rating to the stock. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus price target of $653.23.

Insider Buying and Selling at Thermo Fisher Scientific

In other news, EVP Gianluca Pettiti sold 300 shares of the stock in a transaction on Tuesday, February 4th. The shares were sold at an average price of $585.59, for a total transaction of $175,677.00. Following the completion of the sale, the executive vice president now directly owns 16,363 shares in the company, valued at $9,582,009.17. This represents a 1.80 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Also, CFO Stephen Williamson sold 9,825 shares of the stock in a transaction on Tuesday, February 4th. The stock was sold at an average price of $585.59, for a total transaction of $5,753,421.75. Following the sale, the chief financial officer now owns 27,296 shares of the company’s stock, valued at approximately $15,984,264.64. This trade represents a 26.47 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders sold 23,900 shares of company stock worth $13,106,062. 0.34% of the stock is currently owned by company insiders.

Thermo Fisher Scientific Stock Down 0.5 %

Shares of TMO opened at $519.30 on Tuesday. The firm has a market cap of $195.91 billion, a P/E ratio of 31.42, a price-to-earnings-growth ratio of 2.99 and a beta of 0.79. The company has a debt-to-equity ratio of 0.59, a quick ratio of 1.29 and a current ratio of 1.66. The firm’s 50-day simple moving average is $548.20 and its 200 day simple moving average is $558.14. Thermo Fisher Scientific Inc. has a 52 week low of $493.30 and a 52 week high of $627.88.

Thermo Fisher Scientific (NYSE:TMO) last issued its quarterly earnings data on Thursday, January 30th. The medical research company reported $6.10 EPS for the quarter, beating the consensus estimate of $5.94 by $0.16. Thermo Fisher Scientific had a net margin of 14.78% and a return on equity of 17.51%. On average, analysts forecast that Thermo Fisher Scientific Inc. will post 23.28 earnings per share for the current year.

Thermo Fisher Scientific Increases Dividend

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, April 15th. Shareholders of record on Friday, March 14th will be given a $0.43 dividend. This is a boost from Thermo Fisher Scientific’s previous quarterly dividend of $0.39. This represents a $1.72 annualized dividend and a yield of 0.33%. The ex-dividend date is Friday, March 14th. Thermo Fisher Scientific’s dividend payout ratio is 10.41%.

About Thermo Fisher Scientific

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.